Recognition of an impairment loss (consolidated financial results) and a valuation loss on shares of a subsidiary (standalone financial statements)
musica lab株式会社 (the Company's consolidated subsidiary), the filing company (standalone financial statements)
Goodwill related to musica lab株式会社 and the Company's shares in that company
Sales in some core categories have remained below the initial plan, among other factors, and costs increased due to personnel hiring and other measures aimed at promoting sales activities. As a result, the earnings initially anticipated could no longer be expected.
Approximately ¥105 million (impairment loss on goodwill and extraordinary loss in the consolidated financial statements); approximately ¥109 million (valuation loss on shares of a subsidiary and extraordinary loss in the standalone financial statements)
Second-quarter consolidated accounting period of the fiscal year ending December 2026 (1 April 2026 to 30 June 2026)
The Company does not disclose a consolidated earnings forecast. The impairment loss is reflected in the earnings report for the second quarter of the fiscal year ending December 2026 published today. If the Company becomes able to disclose a reasonable earnings forecast in the future, it will make a disclosure promptly.
The consolidated earnings forecast is not disclosed at this time. The Company intends to make a disclosure promptly if it becomes able to disclose a reasonable earnings forecast.
| Item | Details |
|---|---|
| Event name | Recognition of an impairment loss (consolidated financial results) and a valuation loss on shares of a subsidiary (standalone financial statements) |
| Date of occurrence | Second-quarter consolidated accounting period of the fiscal year ending December 2026 (1 April 2026 to 30 June 2026) |
| Subject Entity | musica lab株式会社 (the Company's consolidated subsidiary), the filing company (standalone financial statements) |
| Target Locations / Products | Goodwill related to musica lab株式会社 and the Company's shares in that company |
| Cause | Sales in some core categories have remained below the initial plan, among other factors, and costs increased due to personnel hiring and other measures aimed at promoting sales activities. As a result, the earnings initially anticipated could no longer be expected. |
| Amount of Impact on Business Performance | Approximately ¥105 million (impairment loss on goodwill and extraordinary loss in the consolidated financial statements); approximately ¥109 million (valuation loss on shares of a subsidiary and extraordinary loss in the standalone financial statements) |
| Accounting period in which recognized | Second-quarter consolidated accounting period of the fiscal year ending December 2026 (1 April 2026 to 30 June 2026) |
| Impact on Earnings Forecast | The Company does not disclose a consolidated earnings forecast. The impairment loss is reflected in the earnings report for the second quarter of the fiscal year ending December 2026 published today. If the Company becomes able to disclose a reasonable earnings forecast in the future, it will make a disclosure promptly. |
| Outlook | The consolidated earnings forecast is not disclosed at this time. The Company intends to make a disclosure promptly if it becomes able to disclose a reasonable earnings forecast. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales in some of musica lab株式会社's core categories fell below expectations, while costs increased due to personnel hiring and other measures aimed at promoting sales activities. As a result of revising the plan, the earnings initially anticipated could no longer be expected.